The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
Open accessPublished version of a preprint
Abstract
Background: Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones. Methods: Using data from the Parkinson’s Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains (“walking and balance”; “motor complications”; “cognition”; “autonomic dysfunction”; “functional dependence”; “activities of daily living”). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression. Results: Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age ( p < 0.0001), greater MDS-UPDRS total scores ( p < 0.0001), higher GDS-15 depression scores ( p = 0.0341), lower dopamine transporter binding ( p = 0.0043), and lower CSF total α-synuclein levels ( p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone ( p = 0.1639). Conclusion: Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large-scale initiatives such as the UK Biobank (including 100 000 participants) (Sudlow et al., 2015), ADNI (Mueller et al., 2005), and Parkinson’s Progression Markers Initiative (PPMI) (Brumm et al., 2023) exemplify progress in neuroimaging diversity; however, significant disparities persist in racial, socioeconomic, and rare dementia representations”
From Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine (2026) · cites this paper as Brumm et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“Outcomes measures comprised by a composite of clinically relevant events have been applied in other areas of medicine—including cancer [36], cardiology [37], nephrology [38], and stroke [39]—and have been acceptable to regulators [40].”
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Benardete, E. A., & Nair, A. K. (2015) · Cerebrovascular Diseases Extra · doi:10.1159/000370060 · Cited by 2,546
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationThe Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) · Movement Disorders · doi:10.1002/mds.10473 · Cited by 1,810
Research works printed but not linked: 5
- Fahn S, 1987, Recent Dev Parkinsons Dis, 2, 153
- Poewe W, 2006, J Neurol, 253, VII2
- McDermott MP, 1995, Arch Neurol, 52, 565
- Kang JH, 2013, JAMA Neurol, 70, 1277
- Food and Drug Administration, 2017, Multiple endpoints in clinical trials: Guidance for industry
Cited by
AI-powered integration of multimodal imaging in precision medicine for neuropsychiatric disorders
Huang, W., & Shu, N. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102132 · Cited by 85
Dam, T., Pagano, G., Brumm, M. C., Gochanour, C., Poston, K. L., Weintraub, D. A., Chahine, L. M., Coffey, C. S., Tanner, C. M., Kopil, C., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00789-w · Cited by 56
Self-citationLoss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease
Espay, A. J., & Lees, A. J. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106077 · Cited by 51
Suárez, P. R., del Campo, N., Bénatru, I., Moreau, C., Desjardins, C., Sánchez‐Ferro, Á., & Fabbri, M. (2024) · Movement Disorders · doi:10.1002/mds.30056 · Cited by 46
Iqbal, M. K., Khan, B., Hifsa, H., YuXuan, G., Mujahid, M., Kiyani, M. M., Khan, H. R., & Bashir, S. (2024) · ACS Omega · doi:10.1021/acsomega.4c06546 · Cited by 38
Metadata
- Authors
- Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O’Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., Coffey, C. S., & Initiative, O. B. O. T. P. P. M.
- Affiliations
- University of Iowa (US)
- University of Pennsylvania (US)
- Northwestern University (US)
- Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA
- University of Pittsburgh (US)
- Universitätsmedizin Göttingen (DE)
- Indiana University Indianapolis (US)
- University of California San Diego (US)
- Michael J. Fox Foundation (US)
- Stanford Medicine (US)
- San Francisco VA Medical Center (US)
- Philadelphia VA Medical Center (US)
- University of Rochester Medicine (US)
- Institute for Neurodegenerative Disorders (US)
- Corresponding author
- Brumm, Michael C.
- ORCID
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2023-07-12
- Volume
- 13
- Issue
- 6
- Pages
- 899-916
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC10578214
- OpenAlex
- W4384301272
- Cited by
- 70
- References
- 58
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 17 · 2023: 1
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Biogen
- CHDI Foundation
- Teva Pharmaceutical Industries
- Celgene
- University of Pennsylvania
- University of Pittsburgh
- International Parkinson and Movement Disorder Society
- Demensförbundet
- Jazz Pharmaceuticals
- Parkinson's Foundation
- Acorda Therapeutics
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Deutsche Forschungsgemeinschaft
- Eisai
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Deutsche Parkinson Vereinigung
- National Institutes of Health
- Genentech
- Allergan
- Sanofi Genzyme
- Avid Radiopharmaceuticals
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease progression, Parkinson's Progression Markers Initiative, de novo Parkinson's disease, predictors of progression, motor complications, cognitive impairment, functional dependence, autonomic dysfunction, activities of daily living, depression, dopamine transporter imaging, MDS-UPDRS, symptomatic treatment, disability
- MeSH terms
- Cognition, Humans, Parkinson Disease, Biomarkers, Disease Progression, Primary Dysautonomias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. https://app.cochat.ai/papers/10.3233/jpd-223433
- The paper
- Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O’Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., . . . Initiative, O. B. O. T. P. P. M. (2023). Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-223433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.